2019, December 6-7: Updates From The New WHO Classification Of Soft Tissue And Bone Tumors
Dec. 6-7, 2019 - Palm Springs, California
15 CME / 15 SAMs
THIS COURSE IS NOW SOLD OUT. PLEASE NOTIFY TERESA POWERS AT firstname.lastname@example.org FOR WAITLIST OPPORTUNITIES.
The diagnosis of soft tissue and bone tumors can be a significant challenge, even to the experienced surgical pathologist, due to the rarity of such tumors, the broad morphological spectrum of mesenchymal neoplasms, and overlap with other soft tissue and bone tumors and non-mesenchymal neoplasms. The classification of soft tissue and bone tumors continues to evolve, following the description of "new" tumor types, the discovery of novel molecular genetic alterations, and the development of increasingly specific diagnostic immunohistochemical markers; these changes are included in the new World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone. Surgical pathologists are not familiar with the current classification of soft tissue and bone tumors and recently developed diagnostic markers and struggle with accurate diagnosis. This course, presented by experts, will help to alleviate that struggle and provide pragmatic information for immediate practice improvement.
- Review update in soft tissue and bone tumors based on the new WHO classification
- Apply recently developed immunohistochemical markers for the diagnosis of soft tissue and bone tumors
- Understand the role of recently identified molecular genetic alterations in the diagnosis of soft tissue and bone tumors
- Jason L. Hornick, MD, PhD
Harvard Medical School
- Jessica L. Davis, MD
Oregon Health & Science University
- G. Petur Nielsen, MD
Harvard Medical School
- Khin Thway, MD, FRCPath
Royal Marsden Hospital, London
CONTINUING MEDICAL EDUCATION AND CONTINUING CERTIFICATION
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Physicians can earn a maximum of 15 SAM credit hours.
USCAP records courses at the Interactive Learning Center for future educational purposes. By registering for this course, you consent that your likeness may be used by USCAP.
Cancellations will be assessed an administrative charge of 25% of the total registration fee. There will be no refunds for cancellations within 14 days of the event. The Academy is not responsible for travel expenses incurred as a result of an event cancellation.